

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A multivalent antiviral vaccine comprising one or more dry and heat-inactivated influenza antigens denatured at higher than 60°C and influenza-infected denatured cells, wherein at least one influenza antigen is capable in producing an immune response in a host when said vaccine is administered orally at a dose that is sufficient for preventing or treating the viral disease in said host.
2. (Canceled)
3. (Currently Amended) A composition for eliciting an immune response to a viral pathogen, said composition comprising viral pathogen said composition comprising dry viral pathogen denatured at higher than 60°C and pathogen-infected denatured cells, and formulated as an oral pill wherein the viral pathogen is selected from the group consisting of: baculovirus, human immunodeficiency virus, influenza virus, rabies virus, and cytomegalovirus.
4. (Canceled)
5. (Currently Amended) A dry immunogen denatured at higher than 60°C and formulated as an oral pill, wherein upon oral administration, said immunogen retains the ability to elicit an immune response in a host, wherein the immunogen comprises pathogen-infected denatured cells.
6. (Previously Presented) The immunogen of claim 5 formulated without an immune adjuvant.

7. (Currently Amended) The immunogen of claim 5 wherein said immunogen pathogen is selected from the group consisting of immunogens derived from fungi, influenza virus, cytomegalovirus, avian leukosis-sarcoma virus, Rous Sarcoma virus, Mammalian C-type Murine leukemia virus, Feline leukemia virus, simian sarcoma virus, B-type Mouse mammary tumor virus, D-type virus, Mason-Pfizer monkey virus, simian AIDS virus, Human T-cell leukemia virus, Simian T-cell leukemia virus, bovine leukemia virus, Human immunodeficiency virus, Simian immunodeficiency virus, Feline immunodeficiency virus, Visna/maedi virus, Equine infectious anemia virus, Caprine arthritis-encephalitis virus, spumavirus, foamy virus, endogenous retrovirus, papilloma virus, respiratory syncytial virus, poliomyelitis virus, pox virus, measles virus, arbor virus, Coxsackie virus, herpes virus, hantavirus, hepatitis virus, baculovirus, mumps virus, circovirus, arenavirus, rotavirus, Colorado Tick Fever CTF virus, Eyach virus, Langat virus, Powassan virus, Omsk hemorrhagic fever virus, Crimean-Congo hemorrhagic fever virus, Yellow fever virus, Encephalitis virus, St. Louis Encephalitis virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, Chikungunya virus, Japanese encephalitis virus, West Nile virus, Kyasanur forest disease virus, Dengue fever virus, California encephalitis virus, adenovirus, Korean haemorrhagic fever virus, hantavirus, Argentine haemorrhagic fever virus, Junin virus, Aujeszky disease virus, Pseudorabies virus, Herpesvirus, cowpox virus, ebolavirus, Ganjam virus, herpesvirus simiae, Lassa fever virus, Louping ill virus, Lymphocytic choriomeningitis virus, Marburg virus, Milkers nodule virus, Newcastle disease virus, Omsk haemorrhagic fever virus, Orf virus, Parvovirus, Pseudorabies, Rabies virus, Rift Valley fever virus, Russian Spring-Summer encephalitis virus, Sabia virus, vaccinia virus, vesicular stomatitis virus, and Western equine encephalitis virus.

8. (Previously Presented) The immunogen of claim 5 wherein said immune response is directed against viral infection.

9. (Previously Presented) The immunogen of claim 5 wherein the immunogen comprised in said pill is between about 0.0000001% to about 20% by weight.

10. (Withdrawn) An oral composition suitable for treating or preventing a pathogen-induced infection in a host, the composition comprising a first component comprising a denatured antigen of an infection-inducing pathogen and a second component comprising a denatured tissue from a pathogen-infected host.
11. (Withdrawn) The oral composition of claim 10 said composition further comprising calcium.
12. (Withdrawn) The oral composition of claim 11 said composition further comprising magnesium.
13. (Previously presented) The multivalent antiviral vaccine of claim 1 further comprising calcium, magnesium, or both.
14. (Previously presented) The composition of claim 3 wherein the viral pathogen is an influenza pathogen.
15. (Previously presented) The immunogen of claim 5 wherein the said immunogen is selected from the group consisting of: baculovirus, human immunodeficiency virus, influenza virus, rabies virus, and cytomegalovirus.
16. (Previously presented) The immunogen of claim 5 wherein said immunogen is an influenza immunogen.